Enterprise Value

22.3M

Cash

44.23M

Avg Qtr Burn

-10.51M

Short % of Float

3.36%

Insider Ownership

0.31%

Institutional Own.

9.39%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CRB-701 Details
Solid tumor/s, Urothelial cancer

Phase 1

Initiation

CRB-601 Details
Solid tumor/s

IND

Submission

Lenabasum Details
Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease

Failed

Discontinued

Lenabasum Details
Cystic fibrosis

Failed

Discontinued

Lenabasum Details
Systemic sclerosis

Failed

Discontinued

Failed

Discontinued